Cytodyn Inc (CYDY)

[Apollo_]

$ Raise, New Board Member - New Listing

OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced CytoDyn, Inc. (OTCQB: CYDY) is verified for trading on OTCQB®, the venture marketplace for entrepreneurial and development stage companies, as of October 2, 2014.

http://www.otcmarkets.com/stock/CYDY/news?id=88911


On September 26, 2014, the Company sold the Note in the principal amount of $2,000,000 to AVCP in a private placement in exchange for
cash in an equal amount. The principal amount of the Note plus unpaid accrued interest is convertible at the election of the holder into shares of
the Company’s common stock at any time prior to maturity at an initial conversion price of $1.00 per share. The conversion price is subject to
(i) adjustment for stock splits and similar corporate events and (ii) reduction to a price per share that is 10% below the lowest sale price that is
below $.9444 per share, for shares of CytoDyn common stock sold in future securities offerings, if any, including sales to AVCP and its
designees. Additional terms of the Note are described under Item 2.03 above, which information is incorporated herein by reference.
As part of the AVC Investment, the Company issued warrants to AVCP to purchase a total of 250,000 shares of the Company’s common
stock exercisable at a price of $0.50 per share. The warrants are currently exercisable in full, include a cashless exercise feature, and will expire
on December 31, 2019.
Under the Subscription Agreement, together with a side letter agreement between the Company and AVCM, AVCM and its designees have
the right, but not the obligation, to invest up to an additional $6.0 million on the same terms as the initial $2.0 million AVC Investment until December 31, 2014 ....

http://ir.cytodyn.com/all-sec-filings

CytoDyn Appoints Carl Dockery to Board of Directors

The Alpha Venture Capital investment limited partnerships managed by Mr. Dockery beneficially own approximately 9.5% of the Company's outstanding common stock, including a recent $2 million investment.

http://www.cytodyn.com/media/press-releases/detail/164/cytodyn-appoints-carl-dockery-to-board-of-directors